Crescent Biopharma, Inc.
CBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001253689
In the last 90 days, Crescent Biopharma, Inc. insiders filed 1 open-market purchase and 7 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $532.6M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Crescent Biopharma, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- +11 vs. Q2 2025
- Shares held
- 11.3M
- +567.1K (+5.3%) vs. Q2 2025
- Total value
- $134.6M
- −$39.0M (−22.4%) vs. Q2 2025
- New holders
- 15
- 7 more added
- Sold out
- 4
- 8 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 82 | $532.6M |
| Q1 2026 | 63 | $476.6M |
| Q4 2025 | 58 | $285.9M |
| Q3 2025 | 41 | $134.6M |
| Q2 2025 | 30 | $173.5M |
| Q1 2025 | 35 | $6.46M |
| Q4 2024 | 41 | $7.56M |
| Q3 2024 | 36 | $3.00M |
| Q2 2024 | 35 | $7.20M |
| Q1 2024 | 69 | $110.5M |
| Q4 2023 | 58 | $82.8M |
| Q3 2023 | 49 | $52.1M |
| Q2 2023 | 55 | $61.9M |
| Q1 2023 | 54 | $46.6M |
| Q4 2022 | 48 | $83.3M |
| Q3 2022 | 35 | $14.3M |
| Q2 2022 | 37 | $15.8M |
| Q1 2022 | 44 | $31.2M |
| Q4 2021 | 47 | $42.7M |
| Q3 2021 | 48 | $64.9M |
| Q2 2021 | 58 | $72.5M |
| Q1 2021 | 78 | $110.4M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Crescent Biopharma, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 1,414,680 | $16.8M | 0.00% | +4900.0% | Added |
| Fairmount Funds Management LLC | 1,387,866 | $16.5M | 1.48% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,387,864 | $16.5M | 0.93% | 00.0% | Unchanged |
| BVF Inc | 1,387,863 | $16.5M | 0.67% | 00.0% | Unchanged |
| Tang Capital Management LLC | 679,824 | $8.08M | 0.31% | +629,672+1,255.5% | Added |
| Vanguard Group Inc | 657,900 | $7.82M | 0.00% | +657,900 | New |
| Logos Global Management LP | 600,000 | $7.13M | 0.70% | +46,314+8.4% | Added |
| Perceptive Advisors LLC | 453,686 | $5.39M | 0.16% | 00.0% | Unchanged |
| Deep Track Capital, LP | 453,686 | $5.39M | 0.15% | 00.0% | Unchanged |
| Boxer Capital Management, LLC | 453,686 | $5.39M | 1.72% | 00.0% | Unchanged |
| Commodore Capital LP | 450,829 | $5.36M | 0.26% | −2,857−0.6% | Reduced |
| Price T Rowe Associates Inc | 383,595 | $4.56M | 0.00% | +383,595 | New |
| Driehaus Capital Management LLC | 302,457 | $3.60M | 0.03% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 272,951 | $3.25M | 0.10% | −180,734−39.8% | Reduced |
| Adage Capital Partners GP, L.L.C. | 200,005 | $2.38M | 0.00% | +99,093+98.2% | Added |
| Soleus Capital Management, L.P. | 200,000 | $2.38M | 0.13% | −200,000−50.0% | Reduced |
| BlackRock, Inc. | 109,115 | $1.30M | 0.00% | +103,064+1,703.3% | Added |
| Jefferies Financial Group Inc. | 102,714 | $1.22M | 0.01% | +75,618+279.1% | Added |
| Blackstone Group Inc. | 75,614 | $899.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 69,134 | $822.0K | 0.00% | +69,134 | New |
| Marshall Wace, LLP | 43,694 | $519.5K | 0.00% | +43,694 | New |
| Goldman Sachs Group Inc | 36,975 | $439.6K | 0.00% | +36,975 | New |
| Two Sigma Investments, LP | 28,318 | $336.7K | 0.00% | +28,318 | New |
| Renaissance Technologies LLC | 26,900 | $319.8K | 0.00% | +26,900 | New |
| Citadel Advisors LLC | 25,593 | $304.3K | 0.00% | +25,593 | New |
| Manufacturers Life Insurance Company, The | 24,923 | $296.3K | 0.00% | +24,923 | New |
| State Street Corp | 18,617 | $221.4K | 0.00% | +18,617 | New |
| Affinity Asset Advisors, LLC | 17,998 | $214.0K | 0.02% | −262,033−93.6% | Reduced |
| Wellington Management Group LLP | 17,698 | $210.4K | 0.00% | −162,188−90.2% | Reduced |
| Northern Trust Corp | 16,816 | $199.9K | 0.00% | +16,816 | New |
| UBS Group AG | 12,661 | $150.5K | 0.00% | +12,438+5,577.6% | Added |
| Bank of America Corp | 3,863 | $45.9K | 0.00% | −5,368−58.2% | Reduced |
| Citigroup Inc | 798 | $9.49K | 0.00% | +798 | New |
| Tower Research Capital LLC (TRC) | 200 | $2.38K | 0.00% | +200 | New |
| Morgan Stanley | 145 | $1.72K | 0.00% | −15,249−99.1% | Reduced |
| Group One Trading, L.P. | 82 | $975 | 0.00% | −80−49.4% | Reduced |
| SBI Securities Co., Ltd. | 68 | $809 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 26 | $374 | 0.00% | +26 | New |
| JPMorgan Chase & Co | 17 | $202 | 0.00% | +17 | New |
| BNP Paribas Arbitrage, SA | 4 | $48 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 20 | $0 | 0.00% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −642,721−100.0% | Sold out |
| Braidwell LP | 0 | $0 | 0.00% | −261,504−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −286−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |